Showing results (51-60 of 57) with videos related to
Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 57 results.
Molecular Immunology|September 6, 2005
MT110: a novel bispecific single-chain antibody construct with high efficacy in eradicating established tumorsKlaus Brischwein, Bernd Schlereth, Benjamin Guller, et al.Science (New York, N.Y.)|August 16, 2008
Tumor regression in cancer patients by very low doses of a T cell-engaging antibodyRalf Bargou, Eugen Leo, Gerhard Zugmaier, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 18, 2016
Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I StudyMaria-Elisabeth Goebeler, Stefan Knop, Andreas Viardot, et al.Protein Engineering, Design & Selection : PEDS|July 27, 2006
A highly stable polyethylene glycol-conjugated human single-chain antibody neutralizing granulocyte-macrophage colony stimulating factor at low nanomolar concentrationEva-Maria Krinner, Julia Hepp, Patrick Hoffmann, et al.Blood|October 2, 2012
Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALLMax S Topp, Nicola Gökbuget, Gerhard Zugmaier, et al.Immunotherapy|November 11, 2020
Pasotuxizumab, a BiTE® immune therapy for castration-resistant prostate cancer: Phase I, dose-escalation study findingsHorst-Dieter Hummel, Peter Kufer, Carsten Grüllich, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 18, 2011
Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survivalMax S Topp, Peter Kufer, Nicola Gökbuget, et al.Pageof 6